Nymox to Report Results of New Phase 2 Study of NX-1207 for BPH

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jan 16, 2008 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that it will be reporting results of a new Phase 2 clinical trial of NX-1207 for benign prostatic hyperplasia (BPH). The Company expects to complete statistical analysis within the next few weeks and will be reporting the results once analysis is complete.

NX-1207 has shown positive results in 3 completed U.S. trials to date. The Company's largest reported trial, a Phase 2 double-blind, placebo controlled, randomized study, showed positive efficacy and safety results for NX-1207 after 3 months in patients with BPH. Overall, patients treated with NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 points reported in published studies of currently approved drugs for BPH and reached statistical significance (p=.017) when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.

NX-1207 has also shown positive results in 5 follow-up studies of available subjects from NX-1207 clinical trials. Patients have shown durable benefits from NX-1207 treatment for up to 3 1/2 years from the date of treatment. The results of a recently completed 2 year double blind follow-up study of subjects from the earlier large Phase 2 trial showed that many patients required no further treatment for 2 years after a single intraprostatic administration of NX-1207 during an office visit. The latter results were statistically significant (p less than .05) when compared to a baseline matched group of placebo controls.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact

Nymox Pharmaceutical Corporation
Roy Wolvin, 1-800-93NYMOX
www.nymox.com

Posted: January 2008

View comments

Hide
(web4)